Latest Posters

This poster explores state-of-the-art nucleic acid detection, the critical steps and the advantages of this approach.

To meet these needs, we developed scalable capture and polishing chromatography steps for recombinant AAV. Here we highlight the polishing step.

The industry has adopted standardized methods for the production and purification of rAAV, streamlining processes for greater efficiency. However, high titers are crucial for meeting demand and cutting costs for therapies that require large doses or have wide patient bases.

Obtaining enough synthetic mRNA for clinical use has long been a hurdle in treating conditions like cancer and infectious diseases.. Current mRNA production methods involve complex purification steps and chemicals, limiting large-scale manufacturing.

Biolayer Interferometry (BLI) technology has greatly advanced the process of antibody discovery, and the latest platforms offer reliable, high precision analysis which researchers can rely on.

This poster highlights several methods by which the downstream purification of viral vectors can be improved using chromatography methods to analyse and purify multiple AAV serotypes.

Recent advancements in affinity technology now support more robust and efficient Protein A chromatography. Hence, the latest Protein A solutions can enhance productivity, yield and accelerate products to market.

Affinity purification platforms such as Protein A or L are well-established in the manufacturing process of therapeutic monoclonal antibodies. However, with the development of engineered modalities such as bi-specific antibodies, fragments and Fc-fusion proteins, challenges in the downstream process of these molecules arise.

Increased demand has led to an overwhelming volume of LC-MS/MS data and a requirement for analytical software that can simplify its interpretation. This poster highlights a new, comprehensive software solution capable of eliminating the otherwise overwhelming efforts of manual data interpretation.

Drug discovery is a time-consuming, resource-intensive part of developing therapeutic targets. This is especially true for commonly considered 'undruggable' targets such as transmembrane proteins.